×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Optimizing Cell and Gene Therapy Clinical Trial Virtualization and Remote Monitoring in the Time of COVID-19
Session Chair(s)
Monica Ravindra Shah, DrMed, FACC
Therapeutic Science and Strategy Unit Vice President and Head, CAGT COE
IQVIA, United States
Using virtual-hybrid and remote solutions, we describe an innovative model for monitoring and executing cell and gene therapy clinical trials during COVID-19. These approaches serve as an instructive path forward for the future of these therapies.
Learning Objective : Describe evolving strategies with innovative solutions for delivering cell and gene therapy trials during COVID-19; Discuss specific areas of trial risk, patient safety, data quality, and how virtual and remote activities are being successfully deployed; Analyze metrics to date and how these support a paradigm shift in the operation of these trials.
Speaker(s)
Industry Update
Chris A Learn, PhD, PMP
Parexel, United States
Vice President, Cell and Gene Therapy Center of Excellence
Industry Update
Erin Finot, MBA, MS
IQVIA, United States
Vice President, Immuno-Oncology
Industry Update
Molly Mjolsness, MBA
Be The Match Biotherapies, United States
Senior Client Delivery Manager
Have an account?